Gastrointestinal Stromal Tumors Treatment Market
1 Introduction to Research & Analysis Reports
1.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Overall Market Size
2.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size: 2021 VS 2028
2.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gastrointestinal Stromal Tumors (GSTs) Treatment Players in Global Market
3.2 Top Global Gastrointestinal Stromal Tumors (GSTs) Treatment Companies Ranked by Revenue
3.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Markets, 2021 & 2028
4.1.2 Surgery
4.1.3 Targeted Therapy
4.1.4 Radiation Therapy
4.1.5 ChemOthersapy
4.1.6 Others
4.2 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue & Forecasts
4.2.1 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2022
4.2.2 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2023-2028
4.2.3 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Ambulatory Surgical Centers
5.1.5 Others
5.2 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue & Forecasts
5.2.1 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2022
5.2.2 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2023-2028
5.2.3 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2021 & 2028
6.2 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue & Forecasts
6.2.1 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2022
6.2.2 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2023-2028
6.2.3 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028
6.3.2 US Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.3.3 Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.3.4 Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028
6.4.2 Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.3 France Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.4 U.K. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.5 Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.6 Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.4.8 Benelux Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028
6.5.2 China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.5.3 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.5.4 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.5.6 India Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028
6.6.2 Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.6.3 Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028
6.7.2 Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.7.3 Israel Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
6.7.5 UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.1.4 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.1.5 Pfizer Key News
7.2 Bayer
7.2.1 Bayer Corporate Summary
7.2.2 Bayer Business Overview
7.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.2.4 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.2.5 Bayer Key News
7.3 Novartis
7.3.1 Novartis Corporate Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.3.4 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.3.5 Novartis Key News
7.4 Immunicum
7.4.1 Immunicum Corporate Summary
7.4.2 Immunicum Business Overview
7.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.4.4 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.4.5 Immunicum Key News
7.5 Roche
7.5.1 Roche Corporate Summary
7.5.2 Roche Business Overview
7.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.5.4 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.5.5 Roche Key News
7.6 AB Science
7.6.1 AB Science Corporate Summary
7.6.2 AB Science Business Overview
7.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.6.4 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.6.5 AB Science Key News
7.7 Arog Pharmaceuticals
7.7.1 Arog Pharmaceuticals Corporate Summary
7.7.2 Arog Pharmaceuticals Business Overview
7.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.7.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.7.5 Arog Pharmaceuticals Key News
7.8 Boston Biomedical
7.8.1 Boston Biomedical Corporate Summary
7.8.2 Boston Biomedical Business Overview
7.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.8.4 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.8.5 Boston Biomedical Key News
7.9 Sun Pharmaceutical
7.9.1 Sun Pharmaceutical Corporate Summary
7.9.2 Sun Pharmaceutical Business Overview
7.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.9.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.9.5 Sun Pharmaceutical Key News
7.10 Natco Pharma
7.10.1 Natco Pharma Corporate Summary
7.10.2 Natco Pharma Business Overview
7.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings
7.10.4 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)
7.10.5 Natco Pharma Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Opportunities & Trends in Global Market
Table 2. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers in Global Market
Table 3. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints in Global Market
Table 4. Key Players of Gastrointestinal Stromal Tumors (GSTs) Treatment in Global Market
Table 5. Top Gastrointestinal Stromal Tumors (GSTs) Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Product Type
Table 9. List of Global Tier 1 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 32. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Bayer Corporate Summary
Table 34. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 35. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 38. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Immunicum Corporate Summary
Table 40. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 41. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Roche Corporate Summary
Table 43. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 44. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 45. AB Science Corporate Summary
Table 46. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 47. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Arog Pharmaceuticals Corporate Summary
Table 49. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 50. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Boston Biomedical Corporate Summary
Table 52. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 53. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Sun Pharmaceutical Corporate Summary
Table 55. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 56. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Natco Pharma Corporate Summary
Table 58. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings
Table 59. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Segment by Type in 2021
Figure 2. Gastrointestinal Stromal Tumors (GSTs) Treatment Segment by Application in 2021
Figure 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in 2021
Figure 8. By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 12. US Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 24. China Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Industry Market Size
